Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges
- 516 Downloads
Following the publication of the randomized controlled but open-label trial Symplicity HTN-2, catheter-based renal sympathetic denervation was proposed as a novel treatment for drug-resistant hypertension. Thousands of procedures were routinely performed in Europe, Australia and Asia, and many observational studies were published. A sudden shift from overoptimistic views to radical scepticism occurred later, when the large US randomized sham-controlled trial Symplicity HTN-3 failed to meet its primary blood pressure lowering efficacy endpoint. Experts are divided on the reasons accounting for the large discrepancy between the results of initial studies and those of Symplicity HTN-3. Indeed, the blood pressure lowering effect associated with renal denervation was overestimated in initial trials due to various patient and physician-related biases, whereas it could have been underestimated in Symplicity HTN-3, which was well designed but not rigorously executed. Still, there is a large consensus on the need to further study catheter-based renal denervation in more controlled conditions, with particular emphasis on identification of predictors of blood pressure response. US and European experts have recently issued very similar recommendations on design of upcoming trials, procedural aspects, drug treatment, patient population and inclusion–exclusion criteria. Application of these new standards may represent a second chance for renal denervation to demonstrate—or not—its efficacy and safety in various patient populations. With its highly standardized treatment regimen, the French trial DENERHTN paved the way for this new approach and may inspire upcoming studies testing novel renal denervation systems in different populations.
KeywordsRenal denervation Renal sympathetic denervation Sympathetic nervous system Resistant hypertension Mild hypertension Ambulatory blood pressure Renal nerve stimulation
Compliance with Ethical Standards
Conflict of Interest
Dr. Azizi reports grants from French Minisitry of Health, Vessix, Boston Scientific Corporation, Medtronic and Servier, and personal fees from Vessix, Boston Scientific Corporation, Medtronic, and Servier. Dr. Kjeldsen reports honoraria from Bayer, MSD, and Takeda. Drs. Persu and Staessen report no conflicst of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.••Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401. In this large US randomised trial including a sham procedure, the benefit assignable to renal denervation was < 3 mmHg, vs. 25–30 mmHg in Symplicity HTN-2 and other previous studies. The main explanation accounting for this large discrepancy is blinding, which minimized patient- and physician-related biases in Symplicity HTN-3. The failure of Symplicity HTN-3 to meet its primary endpoint showed unequivocally that renal denervation is not ready for wide clinical dissemination. Google Scholar
- 4.••Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385(9981):1957–65. This French randomized trial showed a significant −5.9 mmHg additional decrease in daytime ambulatory blood pressure in the renal denervation vs. control arm, leading to a more balanced evaluation of RDN after the “failure” of Symplicity HTN-3. One of the main assets of DENERHTN is that optimum and stepped-care standardized antihypertensive treatment was applied in both arms, both before and after randomisation. CrossRefPubMedGoogle Scholar
- 5.Rosa J, Widimský P, Toušek P, Petrák O, Curila K, Waldauf P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension. 2014;65:407–13.CrossRefPubMedGoogle Scholar
- 8.••Fadl Elmula FE, Jin Y, Yang WY, Thijs L, Lu YC, Larstorp AC, et al. Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. Blood Press. 2015;24(5):263–74. This meta-analysis including 7 randomised controlled trials testing renal denervation using the Symplicity system against maintained or intensified drug treatment alone failed to show a significant advantage of renal denervation. Nevertheless, it cannot rule out a significant benefit of the procedure in a minority of patients. PubMedGoogle Scholar
- 26.••Mahfoud F, Böhm M, Azizi M, Pathak A, Durand Zaleski I, Ewen S, et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J. 2015;36(33):2219–27. A European perspective on the best way to move the renal denervation field forward. CrossRefPubMedGoogle Scholar
- 42.Templin C, Jaguszewski M, Ghadri JR, Sudano I, Gaehwiler R, Hellermann JP, et al. Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre-and post-procedural comparison with the Simplicity® catheter system and the EnligHTN™ multi-electrode renal denervation catheter. Eur Heart J. 2013;34(28):2141–8.PubMedCentralCrossRefPubMedGoogle Scholar
- 50.Karanasos A, Van Mieghem N, Bergmann MW, Hartman E, Ligthart J, van der Heide E, et al. Multimodality intra-arterial imaging assessment of the vascular trauma induced by balloon-based and nonballoon-based renal denervation systems. Circ Cardiovasc Interv. 2015;8(7), e002474.CrossRefPubMedGoogle Scholar
- 56.Dörr O, Liebetrau C, Möllmann H, Gaede L, Troidl C, Rixe J, et al. Soluble fms-like tyrosine kinase-1 and endothelial adhesion molecules (intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1) as predictive markers for blood pressure reduction after renal sympathetic denervation. Hypertension. 2014;63(5):984–90.CrossRefPubMedGoogle Scholar
- 62.•Gal P, de Jong MR, Smit JJ, Adiyaman A, Staessen JA, Elvan A. Blood pressure response to renal nerve stimulation in patients undergoing renal denervation: a feasibility study. J Hum Hypertens. 2014;29(5):292–5. First human study showing the feasibility and safety of renal nerve stimulation as a method to assess the completeness of renal nerve ablation. CrossRefPubMedGoogle Scholar
- 69.Beaussier H, Boutouyrie P, Bobrie G, Frank M, Laurent S, Coudoré F, et al. True antihypertensive efficacy of sequential nephron blockade in patients with resistant hypertension and confirmed medication adherence. J Hypertens. 2015.Google Scholar
- 70.Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015.Google Scholar
- 74.Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100(11):855–61.PubMedCentralCrossRefPubMedGoogle Scholar
- 75.Florczak E, Tokarczyk B, Warchoł-Celińska E, Szwench-Pietrasz E, Prejbisz A, Gosk M, et al. Assessment of adherence to treatment in patients with resistant hypertension using toxicological serum analysis. A subgroup evaluation of the RESIST-POL study. Pol Arch Med Wewn. 2015;125(1–2):65–72.PubMedGoogle Scholar